Back to search
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Acquired Thrombotic Thrombocytopenic Purpura (aTTP) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Acquired Thrombotic Thrombocytopenic Purpura (aTTP) trials you may qualify forThe objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the effi…
The aim of the study is to evaluate the efficacy of a personalized caplacizumab regimen based on ADAMTS13 activity monitoring in adult acquired thrombotic throm…
Primary Objective: To evaluate the effect of caplacizumab on prevention of recurrence of aTTP (proportion of participants with a recurrence of aTTP) during the…
The interpretation of platelet counts has to be revaluated in the light of caplacizumab. By effectively blocking platelet binding sites on VWF-multimers, the na…
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatme…
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) tr…
Open, multi-center, observational, prospective cohort study, only disease-indicated treatment, in patients with clinically diagnosed acquired and congenital TTP…
This study is a multicenter, retrospective, observational study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) treated with plasma exchang…